Genshichiro Fujii

Prostaglandin D2 inhibits the proliferation of human malignant tumor cells

The cytotoxic effect of prostaglandin (PG) D2, PGE1 and PGF2 alpha was examined on human osteosarcoma cells (KSu cell line) in vitro, and PGD2 was most effective. DNA, RNA and protein syntheses of KSu cells were also found to be inhibited by PGD2 at a concentration of 5 micrograms/ml. Furthermore, the proliferation of various human malignant tumor cells was inhibited by PGD2 without exception so far. These results suggest that PGD2 shows an anti-neoplastic effect on a variety of human malignant tumor cells.

Cross-reactive antibodies against human cultured B cells and bovine erythrocytes in human renal transplantation sera.

Sera of 58 recipients of renal allografts were studied for the presence of antibodies against cell cultures of human B lymphoid cell lines (B-LCL) and bovine erythrocytes (BRBC). Cytotoxic anti-B-LCL antibodies were found in 13% of the sera from recipients with the grafts and in 67% of the sera obtained after removal of the rejected grafts. Most of these sera also contained BRBC lysins of high titers. Absorption studies showed that the anti-B-LCL antibodies are directed against antigens shared by BRBC and that they can be absorbed with corresponding graft tissues. The specificity of BRBC lysins found in some of the transplantation sera was shown to be similar to that of Hanutziu-Deicher antibodies.

CLINICAL EXPERIENCES IN THE USE OF BESTATIN IN THE TREATMENT OF LOCALLY ADVANCED CANCERS: CASE REPORT

Publisher Summary This chapter describes a clinical experience in the use of bestatin in the treatment of locally advanced cancers. In the study, both patients had advanced metastatic cancers and chemotherapy had failed. The first case was of breast cancer. The local metastatic tumor with oozing ulcer in the anterior chest wall disappeared almost completely about 2 months after bestatin medication. The other case was of gastric cancer. The ascites accumulation, which had once been reduced by intraperitoneal injection of mitomycin C, was suppressed completely by bestatin medication. The remission period of this case was 2 months. Futraful was administered daily at a dose of 600 mg. A mass was palpated in the upper region of the abdomen 6months postoperatively. Ascites accumulation was noted thereafter. Cytological examination of the ascites showed malignant cells. The chapter presents the effect of bestatin medication on several immune parameters. It was found that skin reactions to purified protein derivative and phytohemagglutinin increased or were maintained at the same positive level as before bestatin medication.